Oppenheimer Initiates Coverage On Pliant Therapeutics with Outperform Rating, Announces Price Target of $40
Oppenheimer analyst Jeff Jones initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Outperform rating and announces Price Target of $40.
RBC Capital Initiates Coverage On Pliant Therapeutics with Outperform Rating, Announces Price Target of $38
RBC Capital analyst Brian Abrahams initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Outperform rating and announces Price Target of $38.
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 22)
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Mid-Day Market Update: Gold Drops 2%; Pliant Therapeutics Shares Jump
Midway through trading Tuesday, the Dow traded down 0.76% to 35,098.84 while the NASDAQ rose 0.09% to 15,376.87. The S&P also fell, dropping 0.33% to 4,520.38.
45 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday.
